



US009408802B1

(12) **United States Patent**
Hartwig

(10) **Patent No.:** **US 9,408,802 B1**
(45) **Date of Patent:** **Aug. 9, 2016**

(54) **SEVEN DAY DRUG IN ADHESIVE
TRANSDERMAL DELIVERY**

(71) Applicant: **ProSolus, Inc.**, San Antonio, TX (US)

(72) Inventor: **Rod L. Hartwig**, Cooper City, FL (US)

(73) Assignee: **ProSolus, Inc.**, San Antonio, TX (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 307 days.

(21) Appl. No.: **13/848,865**

(22) Filed: **Mar. 22, 2013**

Related U.S. Application Data

(60) Provisional application No. 61/614,133, filed on Mar. 22, 2012.

(51) **Int. Cl.**
A61K 9/70 (2006.01)
A61F 13/02 (2006.01)
A61K 9/00 (2006.01)

(52) **U.S. Cl.**
CPC **A61K 9/0014** (2013.01)

(58) **Field of Classification Search**

None

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

5,676,968 A * 10/1997 Lipp et al. 424/448
2006/0078604 A1* 4/2006 Kanios et al. 424/449
2010/0178323 A1* 7/2010 Kydonieus et al. 424/448
2011/0054043 A1* 3/2011 Funaki et al. 514/772.4

* cited by examiner

Primary Examiner — Robert A Wax

Assistant Examiner — Randeep Singh

(74) *Attorney, Agent, or Firm* — Dority & Manning, P.A.

(57) **ABSTRACT**

A transdermal formulation and method of treatment includes providing an active pharmaceutical ingredient, a poly-isobutylene or silicone PSA, optionally, an oil, a crosslinked polyvinylpyrrolidone, and optionally, silicon dioxide, wherein said formulation is prepared on a backing in a three layer transdermal delivery system formulated to provide transdermal delivery and therapeutic levels for up to seven days and optionally with an overlay system required to show bioequivalence.

7 Claims, 7 Drawing Sheets